Form D · Biotechnology

SINGLE CELL TECHNOLOGY, INC.

San Jose, CA · CIK 0001565042

Offering snapshot reported Feb 19, 2021 · SEC filing

Reported sold
$2.14M
Offering amount: $2.15M
Investors reported
15
Form D · investor count
Minimum accepted
$10.2K
Reported outside-investor minimum
First sale
Jan 22, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 19, 2021Initial$2,135,559No comparison15SEC filing
Jul 25, 2013Amendment$323,777$218,777vs Dec 20, 20129SEC filing
Dec 20, 2012Initial$105,000No comparison2SEC filing

Offering details

Securities
Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-389904
The transaction is conversion of promissory notes to common stock. One investor has indicated they may prefer to take partial payment in cash, the rest in stock. Decision is not yet resolved.

Source: Form D, filed Feb 19, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
James O Bowlby Director, Executive, Promoter
James O Bowlby, Jr. Director
Chun Nan Chen Director, Executive
Yen Ming Hsu Director
Richard Jorgensen Director
Ramin Najafi Director
David Sasseen Director
Jun Tien Director
Robert R Tufts Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
6280 San Ignacio Ave., Suite E
San Jose, CA, 95119